2. Others GPCR/G Protein Apoptosis
  3. Isotope-Labeled Compounds Endothelin Receptor Apoptosis
  4. 1258428-05-5

1258428-05-5

Macitentan-d<sub>4</sub> Chemical Structure

1258428-05-5

Chemical Structure

  • Macitentan-d4
  • Synonym(s): ACT-064992-d4
  • CAS No: 1258428-05-5
    Formula: C19H16D4Br2N6O4S
    Molecular Weight: 592.30
  • InChIKey: JGCMEBMXRHSZKX-LZMSFWOYSA-N
  • SMILES: O=S(NCCC)(NC1=NC=NC(OC([2H])([2H])C([2H])([2H])OC2=NC=C(Br)C=N2)=C1C3=CC=C(Br)C=C3)=O

Biological Activity: Macitentan-d4 is a deuterium labeled Sulfamethoxazole. Macitentan is an orally active, non-peptide dual ETA and ETB (endothelin) receptor antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH)[1].

Cat. No. Product Name Purity Description
HY-14184S Macitentan-d4 98.03% Macitentan-d4 is a deuterium labeled Sulfamethoxazole. Macitentan is an orally active, non-peptide dual ETA and ETB (endothelin) receptor antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
HY-14184 Macitentan 99.85% Macitentan (ACT-064992) is an orally active, non-peptide dual ETA and ETB (endothelin receptor) antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
HY-14184R Macitentan (Standard) ≥98% Macitentan (Standard) is the analytical standard of Macitentan. This product is intended for research and analytical applications. Macitentan (ACT-064992) is an orally active, non-peptide dual ETA and ETB (endothelin receptor) antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).

References

[1]. Corallo C, et al. Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study. Arthritis Res Ther. 2016 Oct 6;18(1):228. [Content Brief]

Keywords:

Macitentan-d4MacitentanMacitentan (Standard)